Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback